ArticlePloS one2025
Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsMetabolic-associated steatotic liver disease (MASLD) is a growing global health concern. Although several studies have demonstrated associations between baseline metabolic factors and hepatic steatosis, the quantitative influence of these characteristics on the extent of liver fat reduction following lifestyle modification remains unclear. This study aims to analyse the relationship between baseline factors and the modulation of controlled attenuation parameter (CAP) from baseline to 6 months and compare the mean difference in CAP changes of individuals at a telemedicine-based clinic.
methodsA cohort of MASLD who had hepatic steatosis (CAP ≥ 215 dB/m) with metabolic risk were enrolled. (30 August 2023-30 April 2024). Baseline characteristics, diet and exercise were collected. Multivariable multilevel random intercepts and slope linear regression models were used to analyse the mean difference in CAP change over time for each characteristic adjusted for other variables in the model.
resultsThe mean age was 46.93 years, 70% were females. The baseline CAP value was 319.13 ± 42.33 dB/m. Individual baseline age ≥ 45 (-44.52 dB/m [CI -84.86 to -4.17], p = 0.031); higher waist circumference (-87.85 dB/m [CI -153.23 to -22.47], p = 0.008); and a lower BMI (-78.31 dB/m [CI -139.94 to -16.67], p = 0.013) were associated with greater reductions in the mean difference of CAP change. Notably, participants with diabetes (-61.31 dB/m [CI -100.25 to -22.36], p = 0.002) and better glycemic control (-43.49 dB/m [CI -74.00 to -12.99], p = 0.005) exhibited greater liver fat reductions.
conclusionLifestyle modification led to significant reductions in liver fat, and the extent of improvement was influenced by baseline metabolic characteristics. These findings suggest that metabolic profiles, rather than weight loss alone, determine treatment responsiveness and support the use of individualized lifestyle strategies for MASLD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.